Cost Effectiveness of Adding Fenfluramine to Standard of Care for Patients with Dravet Syndrome in Sweden

Malmberg C, Värendh M, Berling P, Charokopou M, Eklund E

This study evaluated, in a Swedish setting, the cost effectiveness of fenfluramine (FFA) as an add-on to standard of care (SoC) for reducing seizure frequency in Dravet syndrome, a severe developmental epileptic encephalopathy.

Read more and download the article

Applied Health Economics and Health Policy, 2024 Jul;22(4):543-554
DOI: 10.1007/s40258-024-00886-0